Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan and Amlodipine Factorial Study in Essential Hypertension
NCT00425373Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of valsartan and amlodipine in essential hypertension (9 arms), sponsored by Novartis. Primary endpoint: Change in Mean Sitting Diastolic Blood Pressure From Baseline to End of Study at 8 weeks. Started Nov 2006; status: completed.
02
Drugs
valsartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00425373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00425373.